Sonnet BioTherapeutics (NASDAQ:SONN) just reported results for the second quarter of 2024.
- Sonnet BioTherapeutics reported earnings per share of 7 cents. This was below the analyst estimate for EPS of 13 cents.
- The company did not report any revenue for the quarter.